Long-term follow-up study for gene therapy in critical limb ischemia
Part of Heart & circulation, Hormones & metabolism, Skin clinical trials.
This study follows up with people who previously took part in a clinical trial testing an experimental gene therapy for critical limb ischemia (severe leg pain or sores due to blocked arteries). It aims to see how well the treatment works over time. If you were in that earlier trial and received at least one dose, joining this follow-up could help researchers learn more about the therapy's lasting effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in a late-stage (Phase III) trial of the gene therapy treatment called Donaperminogene Seltoplasmid (or NL003) for critical limb ischemia.
- You received at least one dose of the study treatment during that earlier trial.
- You are willing to sign a consent form agreeing to participate.
- You agree to share your medical information and let the researchers collect past or future health data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides access to an experimental cell therapy called PLX-PAD for people with critical limb ischemia (CLI), a severe form of peripheral artery disease that causes leg pain and wounds that don't heal. The treatment aims to improve blood flow and help heal leg ulcers, potentially avoiding amputation.
This trial tests a new type of absorbable scaffold (like a temporary mesh) that is placed inside a blocked artery below the knee to restore blood flow. It is for people with severe leg pain or small ulcers due to chronic limb-threatening ischemia (CLI) who have a short blockage in a specific artery.
This study looks at results of a minimally invasive procedure done inside blood vessels (endovascular therapy) for people with painful or worsening leg artery disease. It uses both past (retrospective) and future (prospective) patient information to better understand outcomes.
This post-market study follows people with significant below-the-knee artery blockages to see how a treatment performs over time. It may help patients by confirming the safety and ongoing effectiveness of the device used for these leg artery problems.
This trial tests a new gene therapy called NXL-001 for people who still have moderate to severe arm or leg weakness 2 to 12 months after a stroke. The treatment aims to help the brain repair itself and improve movement.
This trial tests whether an experimental injection called seltoplasmid, given along with a procedure to restore blood flow in the leg (revascularization), can help heal diabetic foot ulcers that have not responded to standard care. It is designed for people with severe leg artery blockages that threaten the limb.
Hear when a new Peripheral Arterial Disease(PAD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.